Table 6 Incidence (mean) of acute anterior uveitis (AAU) and inflammatory bowel disease (IBD) and respective 95% CIs calculated using a normal approximation. Data from different studies were pooled when the same outcomes from the same treatments were available and when they referred to doses and/or regimens approved in Brazil. * 95% CI reported by the authors of the original study. ** No new case or reactivation was reported in the study with golimumab IV. The incidence of this event was not described in studies with SC golimumab injections
From: The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis – 2019
Outcome | Incidence (events/100 PY) | |||
|---|---|---|---|---|
Drug | AAU Incidence | 95% CI | IBD Incidence | 95% CI |
3.4 | 0.5–6.4 | 0.2 | 0–0.9* | |
7.9 | 5.4–10.5 | 1.3 | 0–4.2* | |
7.4 | 4.7–10.1 | 0.8 | 0.6–2.5* | |
2.2 | 0–5.2 | 0** | – | |
4.9 | 3.0–6.9 | 0.1 | 0–0.3 | |
Secukinumab [142] | 1.0 | 0.3–1.8 | 0.7 | 0.1–1.3 |